EDAP TMS S.A. to Release 2006 First Quarter Financial Results May 10, 2006

LYON, France, May 4  /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), will release its first quarter financial results for the period ending March 31, 2006 on Wednesday, May 10, 2006 after the market close.  The company will host a conference call to discuss the results and answer questions from investors on Thursday, May 11, 2006, at noon Eastern Time, 6:00 p.m. Paris Time.  Representing the Company on the call will be Philippe Chauveau, Chairman of the Board, Hugues de Bantel, Chief Executive Officer, and Thierry Turbant, Chief Financial Officer.

Interested investors may join the call live by dialing [phone] from the United States or [phone] from international locations and entering PIN code 558429#.  Investors may also listen to the live call online at http://www.edap-tms.com/ .

Investors unable to join the call can access a playback of the conference call by telephone or online.  To access the replay, please dial [phone] or [phone] and using access code 173563# beginning one hour after the end of the call until May 18, 2006, or visit the company's Web site at http://www.edap-tms.com/ .

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer.  HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects.  Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option or patients who failed radiotherapy treatment.  The company is also developing this technology for the treatment of certain other types of tumors.  EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Halliburton Investor Relations at [phone], the Corporate Investor Relations Dept at [phone] or see the Company's Web sites at http://www.edap-tms.com/ and http://www.hifu-planet.com/ .

This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties.  These include statements regarding the Company's growth and expansion plans.  Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements.  Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission.  Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

   CONTACT:   EDAP TMS S.A.
              Hugues de Bantel - Philippe Chauveau
              Blandine Confort
              [phone]

              Halliburton Investor Relations
              Matt Kreps - Geralyn DeBusk
              972 458 8000


DATASOURCE: EDAP TMS S.A.



CONTACT:  Hugues de Bantel, or Philippe Chauveau, or Blandine Confort,

all of EDAP TMS S.A., [phone]; or Matt Kreps or Geralyn DeBusk, both

of Halliburton Investor Relations, [phone], for EDAP TMS S.A.



Web site:  http://www.edap-tms.com/

http://www.hifu-planet.com/ 

Copyright